Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?
In a past Free Thinking paper,
we looked at the opportunity and challenges for biosimilar mAbs entering the
rheumatoid arthritis market. A few years later and according to our Therapy
Watch patient record data, uptake of biosimilars remains relatively muted, with
marked inconsistencies across the major European markets. With Enbrel
biosimilar Benepali about to launch across EU, we ask what’s next for RA?